Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

242.85 -4.06 (-1.64%)
Streaming Delayed Price Updated: 11:45 AM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Johnson & Johnson

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Ophthalmoplegia Market expected to rise | Companies – Abbott, Novartis AG, ZEISS International, Valeant Pharmaceuticals International, ALLERGAN, Johnson & Johnson, expected to drive market
Via AB Newswire
News headline image
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
From Alvotech
Via GlobeNewswire
News headline image
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
From Johnson & Johnson
Via Business Wire
News headline image
Smokeless Tobacco Treatment Market to See Booming Growth : Novartis, Pfizer, Johnson & Johnson, Cambrex
Smokeless Tobacco Treatment Comprehensive Study by Type (Keratosis Treatment, Addiction Treatment, Disease Treatment), Application (Hospitals & Clinics, Academic & Research Organizations, Pharmacies),... 
Via SBWire
News headline image
Healthcare Week boon for medical industry
From HKTDC
Via ACN Newswire
News headline image
2022 R&D Spending and Intensity Benchmarks
VIRGINIA BEACH, Va. - June 12, 2023 - PRLog -- According to a newly released study from Schonfeld & Associates, Inc., R&D Ratios & Budgets, the pharmaceutical industry continued to be the biggest R&D... 
Via PRLog
Topics Supply Chain
News headline image
Asia Summit on Global Health gathers 90+ global elites
From HKTDC
Via ACN Newswire
News headline image
Attorney Paul Dagostino Joins Bisnar Chase's Personal Injury Litigation Team
Newport Beach personal injury law firm Bisnar Chase recently welcomed Paul Dagostino to its litigation team. Dagostino's practice focuses on mass tort, class action and product liability cases. He was... 
Via PRLog
Johnson & Johnson (NYSE: JNJ) Making Surprising Moves in Wednesday Session
Via Investor Brand Network
News headline image
Will Dividends Take Center Stage In The Second Half Of 2023?
The NYSE Composite's sideways trade since early 2021 could be a warning sign, suggesting that a shift toward dividend strategies may be prudent. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Tampons Market Is Booming Worldwide : Johnson & Johnson, Kimberly-Clark, Ontex, Unicharm
Tampons Comprehensive Study by Type (Radially Wound Pledget, Rectangular/Square Pad), Distribution Channel (Online, Offline (Supermarkets/Hypermarkets, Independent Retailers, Specialty Stores, Drug... 
Via SBWire
News headline image
Is Novavax Finally Turning Things Around?
Vaccine developer Novavax Inc. (NASDAQ: NVAX) stock shot up 28% following its Q1 2023 earnings report. The company specializes in vaccines for infectious disea 
Via MarketBeat
News headline image
UnitedHealth Group is an AI Stock That Isn't Beating Expectations
Although it's a pioneer in AI, UnitedHealth Group is not enjoying the halo effect on AI stocks, but with more clarity on future growth that should change 
Via MarketBeat
Topics Artificial Intelligence
News headline image
3 Recession-Proof Stocks With Nice Dividends
Certain sectors like consumer staples and health care tend to outperform during economic turbulence. These three stocks are good names to own for the bad times. 
Via MarketBeat
Topics Economy
News headline image
Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
News headline image
J&J Kenvue Spinoff Aims To Give Investors A Healthy Return
Johnson & Johnson spinoff Kenvue had the biggest IPO since 2021, raising $3.8 billion. Kenvue's brands include Band-Aid, Tylenol, Neutrogena and Listerine. 
Via MarketBeat
Topics Initial Public Offering
News headline image
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo. 
Via MarketBeat
News headline image
International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment
From HKTDC
Via ACN Newswire
News headline image
Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering
From Johnson & Johnson
Via Business Wire
News headline image
Discover the Best Stocks to Invest In During a Recession
In times of economic uncertainty, such as during a recession, it can be challenging to know where to invest your 
Via Spotlight Growth
Topics Economy
News headline image
Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference
From Johnson & Johnson
Via Business Wire
News headline image
6 Best Healthcare Stocks to Buy Right Now
Whether you invest in healthcare stocks for pharmaceuticals, medical devices or health insurance, the opportunities are limitless. Learn more with MarketBeat. 
Via MarketBeat
Topics Economy Intellectual Property
News headline image
Why Legend Biotech Stock Is Having Its Best Month Yet
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high. 
Via MarketBeat
News headline image
Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson Earnings Mix Some Good with Some Concerns
Shares of Johnson & Johnson are down as investors digest an earnings report that delivered some good news and some concerns for investors 
Via MarketBeat
Topics Economy
News headline image
Chadd Johnson Joins NFM Influencer Division as Branch Manager
Linthicum, Maryland () April 19, 2023 -- There is a sense that we are on the forefront of changing this industry for the better, and it’s exciting to be part of it. I can’t wait to see what the future... 
Via Prodigy
News headline image
Johnson & Johnson Reports Q1 2023 Results
From Johnson & Johnson
Via Business Wire
News headline image
MarketBeat Week in Review – 4/10 - 4/14
The market continues to seek direction, but the MarketBeat analysts are helping you find opportunities. Here are some of this week's most popular articles. 
Via MarketBeat
Topics Economy
News headline image
Why Next Week's Earnings Report is Good for Johnson & Johnson
Investors have had to digest some negative news headlines, but if you look past that a dividend king like JNJ can be a boring but reliable buy in this market 
Via MarketBeat
Topics Intellectual Property
News headline image
Epic Growth Story Predicted for Pharmaceutical Drug Delivery Market's Future: Johnson & Johnson, Novartis International, Merck
Stay up-to-date with Pharmaceutical Drug Delivery Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.